LONDON – The initial readout points to a remarkable level of effect for Verona Pharma plc's RPL554, which has produced 60 percent additional bronchodilation on top of standard-of-care bronchodilators in a phase IIa study in moderate to severe chronic obstructive pulmonary disease (COPD).